Radiofrequency renal denervation (RF RDN) is a novel therapy for uncontrolled hypertension. In the recent sham‐controlled SPYRAL HTN‐ON MED study, office‐based systolic blood pressure (oSBP) and nighttime BP were reduced significantly. This study examined the cost‐effectiveness of RF RDN in the context of the Japanese healthcare system based on this latest clinical evidence.
